Literature DB >> 10837432

Activity of linezolid against Gram-positive cocci possessing genes conferring resistance to protein synthesis inhibitors.

M Fines1, R Leclercq.   

Abstract

Linezolid belongs to a new class of antimicrobials, the oxazolidinones, that act by inhibiting protein synthesis. To detect cross-resistance with other inhibitors of protein synthesis (chloramphenicol, macrolides, lincosamides, streptogramins, aminoglycosides and tetracyclines), the in vitro activity of linezolid was determined against isolates harbouring known genes conferring resistance to these antimicrobials. Neither the presence of modifying enzymes (LinA, LinA', LinB, Vgb, Vat, SatA, ANT(4') (4")-I, AAC(6')-APH(2"), APHA-3 and Cat), nor the presence of an efflux mechanism (MsrA, MefE, MefA, MreA, Vga, TetK and TeL), nor the modification or protection of antimicrobial target (because of ribosomal methylases or TetM and TetO) affected linezolid activity as demonstrated by similar in vitro activity against resistant isolates and sensitive control isolates.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10837432     DOI: 10.1093/jac/45.6.797

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  15 in total

Review 1.  Resistance to linezolid caused by modifications at its binding site on the ribosome.

Authors:  Katherine S Long; Birte Vester
Journal:  Antimicrob Agents Chemother       Date:  2011-12-05       Impact factor: 5.191

2.  Comparative activities of the oxazolidinone AZD2563 and linezolid against selected recent North American isolates of Streptococcus pneumoniae.

Authors:  Sue E Baum; Sharon A Crawford; M L McElmeel; Cynthia G Whitney; James H Jorgensen
Journal:  Antimicrob Agents Chemother       Date:  2002-09       Impact factor: 5.191

Review 3.  Linezolid: a review of its use in the management of serious gram-positive infections.

Authors:  C M Perry; B Jarvis
Journal:  Drugs       Date:  2001       Impact factor: 9.546

4.  Linezolid resistance in Staphylococcus aureus: gene dosage effect, stability, fitness costs, and cross-resistances.

Authors:  Silke Besier; Albrecht Ludwig; Johannes Zander; Volker Brade; Thomas A Wichelhaus
Journal:  Antimicrob Agents Chemother       Date:  2008-01-22       Impact factor: 5.191

5.  The Cfr rRNA methyltransferase confers resistance to Phenicols, Lincosamides, Oxazolidinones, Pleuromutilins, and Streptogramin A antibiotics.

Authors:  Katherine S Long; Jacob Poehlsgaard; Corinna Kehrenberg; Stefan Schwarz; Birte Vester
Journal:  Antimicrob Agents Chemother       Date:  2006-07       Impact factor: 5.191

6.  Efficacy of linezolid in treatment of experimental endocarditis caused by methicillin-resistant Staphylococcus aureus.

Authors:  C F Dailey; C L Dileto-Fang; L V Buchanan; M P Oramas-Shirey; D H Batts; C W Ford; J K Gibson
Journal:  Antimicrob Agents Chemother       Date:  2001-08       Impact factor: 5.191

7.  Intrapulmonary pharmacokinetics of linezolid.

Authors:  John E Conte; Jeffrey A Golden; Juliana Kipps; Elisabeth Zurlinden
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

8.  Pharmacodynamic activity and efficacy of linezolid in a rat model of pneumococcal pneumonia.

Authors:  Martha J Gentry-Nielsen; Keith M Olsen; Laurel C Preheim
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

9.  Linezolid compared with eperezolid, vancomycin, and gentamicin in an in vitro model of antimicrobial lock therapy for Staphylococcus epidermidis central venous catheter-related biofilm infections.

Authors:  John Curtin; Martin Cormican; Gerard Fleming; John Keelehan; Emer Colleran
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

Review 10.  Linezolid: in infants and children with severe Gram-positive infections.

Authors:  Katherine A Lyseng-Williamson; Karen L Goa
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.